|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2121 K Street, NW, Suite 325 |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20037 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1967-12
|
||||||||
|
6. House ID# 317210000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Lupe Gonzales Jr |
Date | 10/2/2017 2:58:09 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
H.R.1057-Synthetics Trafficking and Overdose Prevention Act of 2017
H.R.2851-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
S.372-Synthetics Trafficking and Overdose Prevention Act of 2017
S.1327-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S.Con.Res.3-A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
H.R.880-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
S.1022-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DIS
16. Specific lobbying issues
H.R.304-Protecting Patient Access to Emergency Medications Act of 2017
H.R.582-Kari's Law Act of 2017
H.R.880-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
H.R.1822-Good Samaritan Health Professionals Act of 2017
H.R.1876-Good Samaritan Health Professionals Act of 2017
S.781-Good Samaritan Health Professionals Act of 2017
S.916-Protecting Patient Access to Emergency Medications Act of 2017
S.1022- Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.304-Protecting Patient Access to Emergency Medications Act of 2017
H.R.372-Competetive Health Insurance Reform Act of 2017
H.R.548-Health Care Safety Net Enhancement Act of 2017
H.R.582-Kari's Law Act of 2017
H.R.817-End Surprise Billing Act of 2017
H.R.849-Protecting Seniors' Access to Medicare Act of 2017
H.R.880-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
H.R.1057-Synthetics Trafficking and Overdose Prevention Act of 2017
H.R.1215-Protecting Access to Care Act of 2017
H.R.1323-Reducing Unnecessary Emergency Room Visits under Medicaid Act
H.R.1421-Improving Access to Medicare Coverage Act of 2017
H.R.1565-Saving Lives, Saving Costs Act
H.R.1628-American Health Care Act of 2017
H.R.1822-Good Samaritan Health Professionals Act of 2017
H.R.1876-Good Samaritan Health Professionals Act of 2017
H.R.2430-FDA Reauthorization Act of 2017
H.R.2851-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
H.J.Res.51-Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act
S.191-Patient Freedom Act of 2017
S.222-Obamacare Replacement Act
S.251-Protecting Medicare from Executive Action Act of 2017
S.260-Protecting Seniors' Access to Medicare Act of 2017
S.284-End Surprise Billing Act of 2017
S.372- Synthetics Trafficking and Overdose Prevention Act of 2017
S.527-Health Care Safety Net Enhancement Act of 2017
S.568-Improving Access to Medicare Coverage Act of 2017
S.781-Good Samaritan Health Professionals Act of 2017
S.916-Protecting Patient Access to Emergency Medications Act of 2017
S.934-FDA Reauthorization Act of 2017
S.1016-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017
S.1022-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act
S.1130-Rural Emergency Acute Care Hospital (REACH) Act
S.J.Res.16-A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act
S.J.Res.17-A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.R.372-Competetive Health Insurance Reform Act of 2017
H.R.1628-American Health Care Act of 2017
S.191-Patient Freedom Act of 2017
S.222-Obamacare Replacement Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
H.R.1057-Synthetics Trafficking and Overdose Prevention Act of 2017
H.R.2851-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
S.372-Synthetics Trafficking and Overdose Prevention Act of 2017
S.1327-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R.2430-FDA Reauthorization Act of 2017
S.934-FDA Reauthorization Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.817-End Surprise Billing Act of 2017
H.R.849-Protecting Seniors' Access to Medicare Act of 2017
H.R.1323-Reducing Unnecessary Emergency Room Visits under Medicaid Act
H.R.1421-Improving Access to Medicare Coverage Act of 2017
H.J.Res.51-Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act
S.251-Protecting Medicare from Executive Action Act of 2017
S.260-Protecting Seniors' Access to Medicare Act of 2017
S.284-End Surprise Billing Act of 2017
S.568-Improving Access to Medicare Coverage Act of 2017
S.1130-Rural Emergency Acute Care Hospital (REACH) Act
S.J.Res.16-A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act
S.J.Res.17-A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
w |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TEC
16. Specific lobbying issues
H.R.582-Kari's Law Act of 2017
S.1016-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
H.R.548-Health Care Safety Net Enhancement Act of 2017
H.R.720-Lawsuit Abuse Reduction Act
H.R.1215-Protecting Access to Care Act of 2017
H.R.1565-Saving Lives, Saving Costs Act
H.R.1822-Good Samaritan Health Professionals Act of 2017
H.R.1876-Good Samaritan Health Professionals Act of 2017
S.527-Health Care Safety Net Enhancement Act of 2017
S.781-Good Samaritan Health Professionals Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gordon |
Wheeler |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Jill |
Openshaw |
|
Congressional Affairs Manager |
|
Jeanne |
Slade |
|
NEMPAC & Grassroots Advocacy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |